10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

RB1CC1 Antibody (Center)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP11791c

Product Information

Application	WB, E
Primary Accession	Q8TDY2
Other Accession	Q9ESK9, NP_001077086.1, NP_055596.3
Reactivity	Mouse
Predicted	Rat, Bovine, Canine, Rabbit, Chicken
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB20844
Calculated MW	183091
Antigen Region	489-515

Additional Information

Gene ID	9821
Other Names	RB1-inducible coiled-coil protein 1, FAK family kinase-interacting protein of 200 kDa, FIP200, RB1CC1, KIAA0203, RBICC
Target/Specificity	This RB1CC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 489-515 amino acids from the Central region of human RB1CC1.
Dilution	WB~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	RB1CC1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	RB1CC1 (HGNC:15574)
Synonyms	KIAA0203, RBICC

Function	Involved in autophagy (PubMed: 21775823). Regulates early events but also late events of autophagosome formation through direct interaction with Atg16L1 (PubMed:23392225). Required for the formation of the autophagosome-like double-membrane structure that surrounds the Salmonella-containing vacuole (SCV) during S.typhimurium infection and subsequent xenophagy (By similarity). Involved in repair of DNA damage caused by ionizing radiation, which subsequently improves cell survival by decreasing apoptosis (By similarity). Inhibits PTK2/FAK1 and PTK2B/PYK2 kinase activity, affecting their downstream signaling pathways (PubMed:10769033, PubMed:12221124). Plays a role as a modulator of TGF-beta-signaling by restricting substrate specificity of RNF111 (By similarity). Functions as a DNA-binding transcription factor (PubMed:12095676). Is a potent regulator of the RB1 pathway through induction of RB1 expression (PubMed:14533007). Plays a crucial role in muscular differentiation (PubMed:12163359). Plays an indispensable role in fetal hematopoiesis and in the regulation of neuronal homeostasis (By similarity).
Cellular Location	Nucleus. Cytoplasm. Cytoplasm, cytosol {ECO:0000250|UniProtKB:Q9ESK9}. Preautophagosomal structure. Lysosome Note=Under starvation conditions, is localized to puncate structures primarily representing the isolation membrane that sequesters a portion of the cytoplasm resulting in the formation of an autophagosome
Tissue Location	Expression levels correlated closely with those of RB1 in cancer cell lines as well as in various normal human tissues Abundantly expressed in human musculoskeletal and cultured osteosarcoma cells.

Background

The protein encoded by this gene interacts with signaling pathways to coordinately regulate cell growth, cell proliferation, apoptosis, autophagy, and cell migration. This tumor suppressor also enhances retinoblastoma 1 gene expression in cancer cells. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

References

Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010)
Guey, L.T., et al. Eur. Urol. 57(2):283-292(2010)
Chano, T., et al. PLoS ONE 5 (6), E11404 (2010) :
Paun, B.C., et al. PLoS ONE 4 (11), E7715 (2009) :
Chan, E.Y. Sci Signal 2 (84), PE51 (2009) :

Images



All lanes: Anti-RB1CC1 Antibody (Center) at 1:1000 dilution + 293T whole cell lysate Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size: 183 KDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.